Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy

Launched by IRCCS EUGENIO MEDEA · Apr 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the brain's activity and structure relate to certain types of epilepsy and specific neurodevelopmental conditions like Angelman Syndrome and Dup15q Syndrome. Researchers want to understand how brain signals, recorded through a test called electroencephalography (EEG), can provide insights into brain function and help identify areas that may be affected by these conditions. By looking at these brain signals before and after treatment, the study aims to see how brain networks change, which could help improve treatments for people who have not responded well to current medications or surgeries.

To participate in this trial, individuals must be between 6 and 75 years old and have a confirmed diagnosis of either focal or generalized epilepsy, Angelman Syndrome, or Dup15q Syndrome. They should also have had a specific type of brain scan and an EEG test done previously. Participants will likely undergo evaluations that include brain imaging and tests to assess their thinking abilities. It's important to note that those with certain types of brain tumors or other specific health issues may not be eligible. Overall, this study could lead to better understanding and treatment options for individuals dealing with these challenging conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • a diagnosis of focal or generalized epilepsy, Angelman syndrome, or Dup15q, confirmed by specialist evaluation;
• • at least one MRI scan of the brain that includes 3D T1 sequences;
• • at least one 128-channel HD-EEG recording; and
• • age between 6 and 75 years at the time of the evaluation of the present study;
• • ability to take part in a neuropsychological evaluation.
• Exclusion Criteria:
• • vascular causes or non-low-grade tumors as causes of epilepsy;
• • age different from the range 6-75 years;
• • neuroradiological examination not complete (absence T1 3D);
• • absence of HD-EEG 128-channel recording
• • inability to take part in a neuropsychological evaluation.